trending Market Intelligence /marketintelligence/en/news-insights/trending/_yykmy7qbn2_eqrkut3mcq2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Syros Pharmaceuticals names director; 2 board members step down

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Syros Pharmaceuticals names director; 2 board members step down

Syros Pharmaceuticals Inc. appointed Michael Bonney to its board of directors.

Bonney is CEO and board chair of biotechnology company Kaleido Biosciences and is also chairman of the boards of Alnylam Pharmaceuticals Inc. and Magenta Therapeutics Inc.

His previous roles include CEO of Cubist Pharmaceuticals LLC, now owned by Merck & Co. Inc., and vice president of sales and marketing at Biogen Inc.

In addition, Syros directors Robert Nelson and Sanj Patel stepped down from the board.

Cambridge, Mass.-based Syros Pharmaceuticals is a biopharmaceutical company focused on cancer and monogenic diseases.